Nu Skin Enterprises, Inc. filings document the company’s operating results, governance, executive leadership changes and financing arrangements. Recent 8-K reports include quarterly and annual financial-result releases, officer appointments and resignations, compensation arrangements, and material definitive agreements tied to amended credit facilities.
The company’s proxy materials provide annual meeting governance and executive-compensation disclosures, including board and compensation matters reported under Schedule 14A. Nu Skin’s regulatory record also reflects its capital structure and liquidity arrangements, including term loan and revolving credit facilities, alongside formal disclosures for its beauty and wellness operations, affiliate platform and Rhyz-related business activities.
Charles Schwab Investment Management Inc. files an Amendment to Schedule 13G reporting 4.45% ownership of Nu Skin Enterprises Class A Common Stock, representing 2,143,294 shares. The filing states sole voting and dispositive power over those 2,143,294 shares. The amendment is signed by Omar Aguilar on 05/13/2026.
Nu Skin Enterprises director Laura Nathanson reported an open-market sale of 2,676 shares of Class A Common Stock at $6.73 per share. After this transaction, she directly holds 30,473 shares. The sale represents a relatively small portion of her reported direct holdings.
Nu Skin Enterprises reported a Form 144 notice concerning proposed sales of Class A common stock executed through William Blair and Company LLC on 05/11/2026 on the NYSE. The filing lists 49,497,715 shares and prior compensatory dispositions of 3,811 and 11,330 Class A shares on 04/30/2024 and 05/29/2025, respectively.
Nu Skin Enterprises reported that Steven K. Hatchett decided to resign as Executive Vice President and Chief Product Officer due to family health circumstances, effective May 8, 2026. He will remain with the company as a strategic product advisor with an annual salary of $147,478.
The filing notes the company’s appreciation for his contributions as Chief Product Officer and confirms that its Chief Financial Officer, Chelsea K. Lantz, signed the report on behalf of the company.
Nu Skin Enterprises reported weaker results for the first quarter of 2026. Revenue fell 12.0% to $320.6 million from $364.5 million, as macroeconomic pressures and its ongoing business transformation reduced consumer spending and customer acquisition. Customers declined 14%, Paid Affiliates 8% and Sales Leaders 13% year over year across its core Nu Skin business.
Net income dropped to $1.8 million, or $0.04 per diluted share, compared with $107.5 million, or $2.14 per diluted share, a year earlier, when results benefited from a large gain on the sale of the Mavely business. The 2026 quarter also included $5.9 million of charges tied to winding down the BeautyBio business.
Gross margin slipped to 66.9%, while selling expenses rose to 34.3% of revenue as the company supported changes to its sales performance plan and the Prysm iO wellness platform rollout. Nu Skin ended the quarter with $200.4 million in cash and current investments, $225 million of total debt under a new credit agreement, and modestly negative operating cash flow.
Nu Skin Enterprises reported weaker results for the first quarter of 2026. Revenue fell 12.0% to $320.6 million from $364.5 million, as macroeconomic pressures and its ongoing business transformation reduced consumer spending and customer acquisition. Customers declined 14%, Paid Affiliates 8% and Sales Leaders 13% year over year across its core Nu Skin business.
Net income dropped to $1.8 million, or $0.04 per diluted share, compared with $107.5 million, or $2.14 per diluted share, a year earlier, when results benefited from a large gain on the sale of the Mavely business. The 2026 quarter also included $5.9 million of charges tied to winding down the BeautyBio business.
Gross margin slipped to 66.9%, while selling expenses rose to 34.3% of revenue as the company supported changes to its sales performance plan and the Prysm iO wellness platform rollout. Nu Skin ended the quarter with $200.4 million in cash and current investments, $225 million of total debt under a new credit agreement, and modestly negative operating cash flow.
Nu Skin Enterprises reported Q1 2026 revenue of $320.6 million, down 12.0% year over year, with a modest +1.1% foreign-exchange benefit. GAAP diluted EPS was $0.04, or $0.14 excluding inventory write-offs, other charges and impairment, compared with $2.14 or $0.23 on an adjusted basis a year ago when results included a large gain from the Mavely sale.
Customers fell 14% to 669,535, Paid Affiliates declined 8% to 120,850, and Sales Leaders decreased 13% to 26,915. Adjusted operating margin was 3.6% versus 6.4% last year. The company returned $2.9 million via dividends and $5.0 million through share repurchases.
For Q2 2026, Nu Skin guides revenue to $330–$360 million with EPS of $0.15–$0.25. Full-year 2026 revenue is projected at $1.35–$1.50 billion and EPS of $0.70–$1.10, or $0.80–$1.20 excluding specified charges, as it invests behind its Prysm iO wellness platform and emerging-market expansion.
Nu Skin Enterprises reported Q1 2026 revenue of $320.6 million, down 12.0% year over year, with a modest +1.1% foreign-exchange benefit. GAAP diluted EPS was $0.04, or $0.14 excluding inventory write-offs, other charges and impairment, compared with $2.14 or $0.23 on an adjusted basis a year ago when results included a large gain from the Mavely sale.
Customers fell 14% to 669,535, Paid Affiliates declined 8% to 120,850, and Sales Leaders decreased 13% to 26,915. Adjusted operating margin was 3.6% versus 6.4% last year. The company returned $2.9 million via dividends and $5.0 million through share repurchases.
For Q2 2026, Nu Skin guides revenue to $330–$360 million with EPS of $0.15–$0.25. Full-year 2026 revenue is projected at $1.35–$1.50 billion and EPS of $0.70–$1.10, or $0.80–$1.20 excluding specified charges, as it invests behind its Prysm iO wellness platform and emerging-market expansion.
Nu Skin Enterprises is asking stockholders to vote at its May 28, 2026 annual meeting on four items: electing nine directors, an advisory vote on executive pay, approving an amended and restated 2024 Omnibus Incentive Plan, and ratifying PricewaterhouseCoopers LLP as auditor for 2026.
The company highlights strong governance practices, including a mostly independent board, separate Chair and CEO roles, a lead independent director, annual board/committee evaluations, and robust risk, cybersecurity and sustainability oversight. Executive pay is heavily performance-based: 2025 cash incentives paid at 21.9% of target after financial metrics came in below minimum levels, while some performance stock units paid out partly or not at all.
In 2025, Nu Skin generated $1.49 billion in revenue with core Nu Skin gross margin of 77.4%, and completed a $250 million sale of its Mavely business, using proceeds to reduce debt and fund innovation. CEO Ryan Napierski’s 2025 compensation was $5.97 million, largely in equity, and 97% of votes supported the prior say-on-pay proposal, which the board views as endorsement of its pay-for-performance design.
NU SKIN ENTERPRISES, INC. Chief Financial Officer Chelsea K. Lantz filed an initial Form 3 reporting her beneficial ownership in the company. The filing shows direct holdings of 42,100 shares of Class A Common Stock, establishing her reported equity position as an executive officer.
Nu Skin Enterprises entered into a new Second Amended and Restated Credit Agreement on March 27, 2026, establishing a $175 million term loan and a $75 million revolving credit facility, each with a five-year term. The term loan was fully drawn at closing and used to repay all amounts outstanding under the prior credit agreement, effectively refinancing the company’s main bank debt.
The revolving facility includes up to $10 million for swingline loans and up to $10 million for letters of credit. Loans bear interest at Term SOFR plus a spread starting at 1.75% or at a base rate plus a spread starting at 0.75%, with both spreads adjustable based on Nu Skin’s consolidated leverage ratio.
The facilities are guaranteed by certain material domestic subsidiaries and secured by liens on the capital stock of material subsidiaries. Key financial covenants require a consolidated leverage ratio not exceeding 2.25 to 1.00 and an interest coverage ratio of at least 3.00 to 1.00, alongside customary restrictions on additional debt, liens, dividends, acquisitions and asset sales.